Ngenbio "Development of Blood-Based Early Diagnosis Prototype for Dementia"

[Asia Economy Reporter Lee Gwan-joo] On the 30th, Ngenbio announced that it has developed a blood-based in vitro diagnostic medical device prototype for early diagnosis using biomarkers discovered through the National Dementia Overcoming Technology Development Project, in which four bio institutions participated as a consortium.

Ngenbio developed a next-generation sequencing (NGS) panel and analysis software capable of early diagnosis of Parkinson's disease dementia and Lewy body dementia. The company explained that this technology can predict genetic factors and risk related to dementia with a single test, making it a technology that can be utilized in various clinical settings related to dementia in the future. Two patents related to this technology were jointly filed with Seoul Asan Medical Center.

Kim Kwang-jung, head of research at Ngenbio, said, “As the world enters an aging era, the demand for early diagnosis of dementia is increasing,” and added, “We will release a product that includes all dementia-related genetic factors currently tested in clinical settings domestically and internationally, and can accurately detect and analyze the relevant genetic variants.”

This content was produced with the assistance of AI translation services.